Related references
Note: Only part of the references are listed.Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels
Javier Ramos-Paradas et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer
Ilaria Alborelli et al.
JOURNAL OF PATHOLOGY (2020)
Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability
Simon Heeke et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort
Nicholas Bevins et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)